Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

Press/Media

Period	22 Oct 2020

Media coverage

Title	Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas
Media name/outlet	OncLive
Country/Territory	United States
Date	22/10/20
URL	https://www.onclive.com/view/dr-schwartz-on-the-benefit-of-dose-reduced-nivolumab-ipilimumab-in-metastatic-sarcomas
Persons	Gary Schwartz